Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (34): 6271-6275.doi: 10.3969/j.issn.1673-8225.2011.34.001

    Next Articles

Vascular endothelial growth factor delivery system combined with bone marrow mesenchymal stem cell induced by osteogenesis for repair of bone defects

Xu Xiao-feng1, Wang Ming-wei2, Pan Xin3, Liu Xiao-ping2, Zhang Zhi-jian4   

  1. 1Department of Orthopaedics, Affiliated Hospital of Jiangsu University, Zhenjiang  212013, Jiangsu Province, China
    2School of Clinical Medicine, Jiangsu University, Zhenjiang  212013, Jiangsu Province, China
    3Zhenjiang Emergency Center, Zhenjiang  212013, Jiangsu Province, China
    4Institute of Basic Medicine and Medical Technology, Jiangsu University, Zhenjiang  212013, Jiangsu Province, China
  • Received:2011-02-01 Revised:2011-03-30 Online:2011-08-20 Published:2011-08-20
  • About author:Xu Xiao-feng, Chief physician, Associate professor, Master’s supervisor, Department of Orthopaedics, Affiliated Hospital of Jiangsu University, Zhenjiang 212013, Jiangsu Province, China FYGOYB@163.com

PDF

493

Abstract:

BACKGROUND: Present studies have reported that the delivery system of growth factors applied in orthopedics is focused on the repair of cartilage. However, the report of using composite tissue engineering bone to repair bone defect is scarce.
OBJECTIVE: To construct a composite scaffold of nano-hydroxyapatite/collagen (nHAC) modified by bone marrow mesenchymal stem cells (BMSCs) with osteogenic induction and controlled releasing vascular endothelial growth factor (VEGF) delivery system constituted of VEGF, heparin (HP) and fibrin (FB), and investigate the effect of repair of bone defect.
METHODS: Composite scaffold delivery system was constructed with different combinations of VEGF, HP and FB. Then osteogenic induced BMSCs were seeded onto the nHAC scaffolds loaded with the optimal controlled releasing VEGF delivery system. Animal models of femoral bone defect were established. A total of 36 SD rats were randomly divided into 3 groups: VEGF/HP/FB/nHAC/BMSCs group, VEGF/HP/FB/nHAC group and control group, all groups administratered with internal fixation. The releasing capacity of VEGF was estimated by ELISA. X ray and alkaline phosphatase (ALP) activity observation were performed at 1, 4, 12, 24 weeks after implantation to evaluate the repair of bone defects in each group.
RESULTS AND CONCLUSION: nHAC modified by controlled releasing drug delivery system constituted of VEGF, HP and FB still released VEGF at a high concentration at 30 days in vitro, and the releasing curve was flat. The composite scaffold in animal model was completely degraded at 24 weeks. Bone defects were repaired well and ALP activity in bone defective parts was significantly higher in VEGF/HP/FB/nHAC/BMSCs group than that in VEGF/HP/FB/nHAC and control groups. nHAC modified by controlled releasing drug delivery system constituted of VEGF, HP and FB has a better releasing characteristic, and the composite scaffold of VEGF/HP/FB/nHAC/MSCs can promote the speed and quality of bone repair in bone defect rat models.

CLC Number: